Design Therapeutics, Inc. (NASDAQ:DSGN) has 114 institutional investors that have filed 13F reports for the period ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 31 Dec, 2025 | 0 | 72,768 | 3.56% | $0.00 |
| BAKER BROS. ADVISORS LP | 31 Dec, 2025 | 0 | 520,217 | 30.37% | $0.00 |
| SR ONE CAPITAL MANAGEMENT, LP | 31 Dec, 2025 | 0 | 0 | 0.00% | $0.00 |
| Barclays Plc | 31 Dec, 2025 | 0 | -97,751 | -52.89% | $0.00 |
| VANGUARD GROUP INC | 31 Dec, 2025 | 0 | 187,209 | 12.97% | $0.00 |
| Point72 Asset Management, L.P. | 31 Dec, 2025 | 0 | 2,031,452 | 60.81% | $0.00 |
| Rockefeller Capital Management L.P. | 31 Dec, 2025 | 0 | 1,476 | 0.00% | $0.00 |
| Almitas Capital LLC | 31 Dec, 2025 | 0 | -1,530,435 | -50.00% | $0.00 |
| Logos Global Management LP | 31 Dec, 2025 | 0 | -1,155,000 | -31.60% | $0.00 |
| RA CAPITAL MANAGEMENT, L.P. | 31 Dec, 2025 | 0 | 985,682 | 207.21% | $0.00 |
| Vivo Capital, LLC | 31 Dec, 2025 | 0 | 1,612,903 | 0.00% | $0.00 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 31 Dec, 2025 | 0 | 103,581 | 9.62% | $0.00 |
| Woodline Partners LP | 31 Dec, 2025 | 0 | 331,327 | 54.08% | $0.00 |
| FMR LLC | 31 Dec, 2025 | 0 | 30,419 | 4.11% | $0.00 |
| Kynam Capital Management, LP | 31 Dec, 2025 | 0 | -244,973 | -23.79% | $0.00 |
| Morgan Stanley | 31 Dec, 2025 | 0 | 526,315 | 299.06% | $0.00 |
| Frazier Life Sciences Management, L.P. | 31 Dec, 2025 | 0 | -1,432,547 | -73.33% | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Dec, 2025 | 0 | -16,023 | -2.30% | $0.00 |
| Elmind Capital, LP | 31 Dec, 2025 | 0 | 207,900 | 0.00% | $0.00 |
| State Street Corp | 31 Dec, 2025 | 0 | 13,239 | 2.09% | $0.00 |